BerandaNBIX • NASDAQ
add
Neurocrine Biosciences Inc
Tutup sebelumnya
$137,73
Rentang hari
$136,70 - $140,73
Rentang tahun
$84,23 - $154,61
Kapitalisasi pasar
13,64Â M USD
Volume Rata-Rata
838,63Â rb
Rasio P/E
40,58
Hasil dividen
-
Bursa utama
NASDAQ
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 687,50Â jt | 16,49% |
Biaya operasional | 286,30Â jt | 18,31% |
Laba bersih | 107,50Â jt | 65,38% |
Margin laba bersih | 15,64 | 42,05% |
Penghasilan per saham | 1,65 | 1,23% |
EBITDA | 152,90Â jt | -1,48% |
Tarif pajak efektif | 32,60% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 975,60Â jt | -6,09% |
Total aset | 3,89Â M | 17,69% |
Total liabilitas | 1,20Â M | 50,23% |
Total ekuitas | 2,69 M | — |
Saham yang beredar | 99,18 jt | — |
Harga terhadap nilai buku | 5,06 | — |
Tingkat pengembalian aset | 9,61% | — |
Tingkat pengembalian modal | 11,72% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | 107,50Â jt | 65,38% |
Kas dari operasi | 102,00Â jt | 57,89% |
Kas dari investasi | -29,00Â jt | -2,84% |
Kas dari pembiayaan | -3,30Â jt | 98,87% |
Perubahan kas bersih | 69,90Â jt | 127,24% |
Arus kas bebas | 25,20Â jt | 126,07% |
Tentang
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Didirikan
1992
Kantor pusat
Situs
Karyawan
1.800
